Home
 /
Papers
 /
Immunology
 /
T cell ectosomes promote antibody responses through cognate TCR-pMHC interactions
Preprint
Open access
V1
Top 1% · Validated by QED

T cell ectosomes promote antibody responses through cognate TCR-pMHC interactions

Fenglei Li, Benjamin Schmitz, Henriette A. Remer +3 more
August 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.07.30.667776
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Immunology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By demonstrating that TCR-enriched ectosomes engage cognate pMHCII on B cells to drive IgG production, this paper reveals a new antigen-specific, contact-independent mode of T cell help and a synthetic platform for vaccine enhancement.

QED claims analysis

Summary

Activated CD4+ T helper cells release TCR-enriched nanoscale membrane vesicles (ectosomes) that are transferred to antigen-primed B cells, where ectosomal TCRs engage and cluster cognate pMHCII complexes to trigger intracellular signaling and class-switched antibody production, constituting a quantitatively substantial mode of T cell help that accounts for approximately 50% of antibody responses and can be synthetically reconstituted to boost immune responses in aged mice.

See full analysis
Main Claim 1 –

Activated OTII Th2 cells release TCR-enriched ectosomes

Supporting evidence

  • T cell ectosomes are lipid-bilayer vesicles with spherical morphology
  • Ectosomes enrich TCR signaling, CD40L, and adhesion proteins
  • ESCRT proteins TSG101 and VPS4B are required for ectosome biogenesis
Main Claim 2 –

Ectosomal TCR engages pMHCII to trigger antigen-specific B cell signaling

Supporting evidence

  • Transferred TCR clusters cognate pMHCII on the B cell surface
Main Claim 3 –

T cell ectosomes drive antigen-specific class-switched IgG production

Supporting evidence

  • Hyperimmunization yields memory-enriched B cells for ectosome assays
Main Claim 4 –

Ectosome-mediated signals provide ~50% of in vitro T cell help

Abstract

Protective antibody-mediated immunity requires effective T cell-mediated help. Recognition of peptide antigens presented by major histocompatibility complex class II molecules (pMHCII), via cognate T cell antigen receptors (TCR), activates CD4+ T helper cells to upregulate expression of CD40L and helper cytokines. CD40L-CD40 interactions at T-B cell synapses and secreted cytokines are well established mediators of T cell help. Whether engaged pMHCII also transmits signals that help B cells remains unresolved. Here, we show that TCR-enriched nanoscale vesicles shed by activated T cells (ectosomes) are transferred to antigen-primed B cells, where they engage and cluster cognate pMHCII, triggering signaling and specific IgG antibody production. Disruption of ectosome release attenuates B cell antibody production, while native and synthetic ectosomes boost antibody responses. We conclude that T cell ectosomes constitute a new modality of help for B cells, delivered through engagement of pMHCII by cognate ectosomal TCR.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?